Zonisamide Viatris (previously Zonisamide Mylan) (zonisamide)
Generic
- Region
- 🇪🇺 EU
- Active substance
- zonisamide
- Company
- Viatris Limited
- Status
- Authorised
- Therapeutic area
- Epilepsy
- CHMP opinion
- Thu 28 Jan 2016
- EU approval
- Thu 31 Mar 2016
- Designations
- Generic
- Application
- EMEA/H/C/004127
- ATC
- N03AX15
- Official record
- www.ema.europa.eu
Indication
Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zonegran Authorised · Amdipharm Limited
Follow Zonisamide Viatris (previously Zonisamide Mylan)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.